Zhejiang Hisun Biomaterials Co. (688203) Fair Value & Analysis
Basic Materials · CN · Market cap 2.5B CNY
Fair value as of: Aug 11, 2026
From 16 valuation models · updated yesterday
Fair value updated Aug 11, 2026, revised from ¥0.9400 to ¥12.02 (+1,178.4%) since Jul 12, 2026. Share price +18.9% over the past month.
Below-average quality, currently priced close to our fair value.
What matters now
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- A fairly wide model range (¥7.92 to ¥15.60) leaves room in how you read the outcome.
Price vs Fair Value (4 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 11, 2026.
How to read this chart
48‑month range ¥7.72 – ¥20.47 · fair‑value band ¥7.92 – ¥15.60 · the ¥11.62 price screens below the ¥12.02 fair value. Dashed = 300-day average. As of Aug 11, 2026.
Analysis
Zhejiang Hisun Biomaterials Co. (688203) currently trades at ¥11.62, while our model-based Fair Value estimate is ¥12.02, implying the stock looks roughly 3.4% fairly valued today. The Quality Score stands at 48/100 (below-average quality), in the Basic Materials sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Zhejiang Hisun Biomaterials Co. generated revenue of 914M CNY at a net margin of 1.2%. Revenue grew 30.3% year over year. It earns a return on equity of 0.7%. Net debt stands at 84.0M CNY. Fundamentals as of Aug 11, 2026
Our scenario range runs from ¥7.92 (bear case) to ¥15.60 (bull case); at ¥11.62, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 34% below its 52-week high and 8% above its 52-week low, currently below its 200-day average. For context, the median of 10 Basic Materials peers we cover trades at -46% fair-value upside, at 3%, 688203 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 16 models by family
Widest divergence: Asset-Based (¥4.88) versus Earnings-Based (¥0.7100). Highest evidence: Residual Income (76).
Notify me when 688203 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 11, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 49 · Market factors (momentum, volatility) 31
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Zhejiang Hisun Biomaterials Co.Ltd. engages in the research, development, production, and sale of polylactic acid in China. Its products are used in various applications that include 3D printing, extrusion, thermoforming, film blowing and laminating, injection molding, meltblown non-woven fabric, and injection blow molding.
Full company description
Zhejiang Hisun Biomaterials Co.Ltd. engages in the research, development, production, and sale of polylactic acid in China. Its products are used in various applications that include 3D printing, extrusion, thermoforming, film blowing and laminating, injection molding, meltblown non-woven fabric, and injection blow molding. The company was founded in 2004 and is headquartered in Taizhou, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Zhejiang Hisun Biomaterials Co. reported revenue of ¥852M in FY2025 versus ¥585M in FY2021, a compound +9.8%/yr. Reported net income was ¥9.9M in FY2025, compounding −27.3%/yr from FY2021.
Watch 688203: get an alert when its fair value changes →
Peer Group
Chemicals · 341 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Chemicals median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Chemicals stocks, each showing price versus our Fair Value estimate (as of Aug 11, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| BASF SE BASN | 1,034 MXN | 532.13 MXN | -49% |
| Ningxia Baofeng Energy Group 600989 | ¥20.32 | ¥20.17 | -1% |
| Zhejiang Juhua Co 600160 | ¥42.85 | ¥23.35 | -46% |
| PT Barito Pacific Tbk, BRPT | 1,690 IDR | 1,628 IDR | -4% |
| LG Chem, Ltd 051910 | 260,500 KRW | 587,755 KRW | +126% |
| Formosa Chemicals & Fibre Corporation 1326 | 66.10 TWD | 6.79 TWD | -90% |
| PTT Global Chemical Public Company PTTGC | 35.50 THB | 18.21 THB | -49% |
| 542812 542812 | ₹4,369 | ₹791.05 | -82% |
| Indorama Ventures Public Company IVL | 24.50 THB | 17.95 THB | -27% |
| Navin Fluorine International Limited NAVINFLUOR | ₹8,650 | ₹2,146 | -75% |
Compare Zhejiang Hisun Biomaterials Co. with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Basic Materials stocks →
Frequently asked questions
Is Zhejiang Hisun Biomaterials Co. (688203) overvalued or undervalued?
What is the fair value of 688203?
What is the quality score of 688203?
What is the revenue of Zhejiang Hisun Biomaterials Co. (688203)?
What is the net profit margin of 688203?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Zhejiang Hisun Biomaterials Co. and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.